Vincerx Pharma, Inc.

WHO'M

Digital Profiler. Simply click the AI button

CUSIP

92731L106

SEDOL

N/A

CIK

0001796129

vincerx.com

LEI:

FIGI: BBG00RRQXMX2

VINC

Vincerx Pharma, Inc.

GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology

PROFILER

NAME

Vincerx Pharma, Inc.

ISIN

US92731L1061

TICKER

VINC

MIC

XNAS

REUTERS

VINC.OQ

BLOOMBERG

VINC US

BUILD THEMEFOLIO SHARE IDEAS DISCUSS

LEVERAGE INVEST

Financial Intelligence

360°^iHub Crowd^iFeed ATH Tracker Index Tracker ETF TF Spicy² X-Billboard

FOR INVESTORS

FOR TRADERS

Securities Trading Warrants

The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.

Mon, 06.01.2025 Vincerx Pharma

US92731L1061

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Vincerx Pharma, Inc. (NasdaqCM: VINC) and Oqory, Inc. Pursuant to the terms of the agreement, at the closing of the transaction, Vincerx equity holders will hold about 5% of the combined co...

Vincerx Pharma

Technical Analysis Termsheet Terminal

Permalink

Mon, 30.12.2024 Vincerx Pharma

US92731L1061

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Vincerx Pharma, Inc. (NASDAQ: VINC) and Oqory, Inc. is fair to Vincerx shareholders. Upon completion of the proposed transaction, Vincerx equity holders will hold about 5% of the combined company. Halper Sadeh encourages Vincerx shareholders to click here to le...

Vincerx Pharma

Technical Analysis Termsheet Terminal

Permalink

Mon, 30.12.2024 Vincerx Pharma

US92731L1061

Ademi LLP is investigating Vincerx (Nasdaq: VINC) for possible breaches of fiduciary duty and other violations of law in its transaction with the Oqory. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In t...

Vincerx Pharma

Technical Analysis Termsheet Terminal

Permalink

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

Legend

SMART * AD

P R O D U C T S U G G E S T I O N S

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Vincerx Pharma, Inc.

VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc. - VINC

VINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Vincerx Pharma, Inc. Is Fair to Shareholders

Shareholder Alert: Ademi LLP Investigates Whether Vincerx Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders

Newsletter